ABSTRACT
Objective To investigate the clinical efficacy of apapatinib-targeted therapy combined with oxaliplatin and tiggio for treatment of gastric cancer. Methods A total of 150 patients with advanced gastric cancer were enrolled from March 2015 to March 2017. According to the random number table method, the patients were divided into the study group (apocitinib combined with oxaliplatin+tiggio) and the control group (oxaliplatin + tiggio), 75 cases each. The recent treatment effects and adverse reactions were compared between the two groups. Results The objective response rate (46.7 % vs. 25.3 %) and disease control rate (76.0 % vs.48.0 %)in the study group and the control group were statistically significant(all P <0.05).There were no statistical differences in the incidence of complications such as myelosuppression, digestive tract reaction, fatigue and oral ulcer between the two groups (all P > 0.05). The incidence of complications such as hypertension, proteinuria and hand-foot syndrome in the study group was higher than those in the control group (all P < 0.05), but it was in a state of grade Ⅰ~Ⅱ and tolerance. Conclusion Apotiphene combined with oxaliplatin and tiggio as a chemotherapy regimen for advanced gastric cancer may have a better effect.